Nasal Drug Delivery Technology Market Analysis Report By Therapeutic Application (Asthma, Rhinitis), By Dosage Form (Powder, Gel, Spray, Drops), By Container Type, And Segment Forecasts, 2019 - 2025
The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR, according to a new report by Grand View Research, Inc. Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market. According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).
Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine. Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market. Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.
Further key findings from the study suggest:
- Nasal sprays led the dosage type segment in 2017 due to increased prevalence of asthma and other infectious diseases
- On the other hand, nasal drops segment witnessed the fastest growth in 2017 owing to availability of cost-effective products with better efficacy
- Non-pressurized containers segment led the market in 2017 due to continous development in nasal powders and gel products
- Asthma was the dominant therapeutic application segment in 2017 and is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast years due to increasing disease prevalence
- Geographically, North America held the largest share in 2017. Asia Pacific is estimated to witness the fastest CAGR of 7.5% due to presence of key companies, such as Cipla Inc.
- Some of the leading companies in the global nasal drug delivery technology market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.
- Chapter 1 Methodology and Scope
- 1.1 Research Methodology
- 1.2 Research Scope and Assumptions
- 1.3 List of Tables
- Chapter 2 Executive Summary
- 2.1 Market Summary
- Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Segmentation
- Chapter 4 Market Definitions
- Chapter 5 Industry Outlook
- 5.1 Market Variable Analysis
- 5.1.1 Increasing preference for nasal drug delivery technology
- 5.1.2 Growing incidence of chronic diseases
- 5.1.3 Growing geriatric population
- 5.2 Market Restraint Analysis
- 5.2.1 Complications associated with the overuse of nasal powders
- Chapter 6 Business Environment Analysis
- 6.1 SWOT Analysis; By factor (Political & legal, economic and technological)
- 6.2 Porter’s Five Forces Analysis
- Chapter 7 Dosage Forms Business Analysis
- 7.1 Nasal Drug Delivery Technology market: Dosage Forms Movement Analysis
- 7.2 Nasal Spray
- 7.2.1 Nasal sprays market estimates and forecast, 2014 - 2025
- 7.3 Nasal Drop
- 7.3.1 Nasal drops market estimates and forecast, 2014 - 2025
- 7.4 Nasal Gel
- 7.4.1 Nasal gels market estimates and forecast, 2014 - 2025
- 7.5 Nasal Powder
- 7.5.1 Nasal powder market estimates and forecast, 2014 - 2025
- Chapter 8 Container Type Business Analysis
- 8.1 Nasal Drug Delivery Technology market: Container Type Movement Analysis
- 8.2 Pressurized container
- 8.3 Pressurized container market estimates and forecast, 2014 - 2025
- 8.4 Non-pressurized container
- 8.5 Non-pressurized container market estimates and forecast, 2014 - 2025
- Chapter 9 Therapeutic Application Business Analysis
- 9.1 Nasal Drug Delivery Technology market: Therapeutic Application Movement Analysis
- 9.2 Nasal Congestion
- 9.2.1 Nasal congestion market estimates and forecast, 2014 - 2025
- 9.3 Rhinitis
- 9.3.1 Rhinitis market estimates and forecast, 2014 - 2025
- 9.4 Asthma
- 9.4.1 Asthma market estimates and forecast, 2014 - 2025
- 9.5 Others
- 9.5.1 Others market estimates and forecast, 2014 - 2025
- Chapter 10 Regional Business Analysis
- 10.1 Nasal Drug Delivery Technology Market: Regional Movement Analysis
- 10.2 North America.
- 10.2.1 North America market estimates and forecast, 2014 - 2025
- 10.2.2 U.S.
- 10.2.2.1 U.S. market estimates and forecast, 2014 - 2025
- 10.2.3 Canada
- 10.2.3.1 Canada market estimates and forecast, 2014 - 2025
- 10.3 Europe
- 10.3.1 Europe market estimates and forecast, 2014 - 2025
- 10.3.2 Germany
- 10.3.3 Germany market estimates and forecast, 2014 - 2025
- 10.3.4 U.K.
- 10.3.5 U.K. market estimates and forecast, 2014 - 2025
- 10.4 Asia-Pacific
- 10.4.1 Asia-Pacific market estimates and forecast, 2014 - 2025
- 10.4.2 Japan
- 10.4.2.1 Japan market estimates and forecast, 2014 - 2025
- 10.4.3 China
- 10.4.3.1 China market estimates and forecast, 2014 - 2025
- 10.4.4 India
- 10.4.4.1 India market estimates and forecast, 2014 - 2025
- 10.5 Latin America
- 10.5.1 Latin America market estimates and forecast, 2014 - 2025
- 10.5.2 Brazil
- 10.5.2.1 Brazil market estimates and forecast, 2014 - 2025
- 10.5.3 Mexico
- 10.5.3.1 Market estimates and forecast, 2014 - 2025
- 10.6 Middle East and Africa
- 10.6.1 Middle-East and Africa market estimates and forecast, 2014 - 2025
- 10.6.2 South Africa
- 10.6.3 South Africa market estimates and forecast, 2014 - 2025
- Chapter 11 Company Profiles
- 11.1 Company Profiles
- 11.1.1 GlaxoSmithkline plc.
- 11.1.1.1 Company overview
- 11.1.1.2 Financial Performance
- 11.1.1.3 Product benchmarking
- 11.1.1.4 Strategic initiatives
- 11.1.2 AstraZeneca
- 11.1.2.1 Company overview
- 11.1.2.2 Financial performance
- 11.1.2.3 Product benchmarking
- 11.1.2.4 Strategic initiatives
- 11.1.3 Pfizer, Inc.
- 11.1.3.1 Company overview
- 11.1.3.2 Financial performance
- 11.1.3.3 Product benchmarking
- 11.1.4 OptiNose
- 11.1.4.1 Company overview
- 11.1.4.2 Product benchmarking
- 11.1.4.3 Strategic initiatives
- 11.1.5 Becton, Dickson and Company
- 11.1.5.1 Company overview
- 11.1.5.2 FINANCIAL PERFORMANCE
- 11.1.5.3 Product benchmarking
- 11.1.6 Promius Pharma
- 11.1.6.1 Company overview
- 11.1.6.2 FINANCIAL PERFORMANCE
- 11.1.6.3 Product Benchmarking
- 11.1.6.4 strategic initiatives
- 11.1.7 B.F. Ascher & Company, Inc.
- 11.1.7.1 Company overview
- 11.1.7.2 Product benchmarking
- 11.1.8 Cadila Pharmaceuticals
- 11.1.8.1 Company overview
- 11.1.8.2 Financial performance
- 11.1.8.3 Product Benchmarking
- 11.1.9 Douglas NZ
- 11.1.9.1 Company overview
- 11.1.9.2 Product benchmarking
- 11.1.10 ENT Technologies Pty. Ltd.
- 11.1.10.1 Company Overview
- 11.1.10.2 Product Benchmarking
- 11.1.11 Pendopharm
- 11.1.11.1 Company Overview
- 11.1.11.2 Product Benchmarking
- 11.1.12 NAVEH Pharma
- 11.1.12.1 Company Overview
- 11.1.12.2 Product Benchmarking
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook